253 reports of this reaction
1.5% of all PYRAZINAMIDE reports
#17 most reported adverse reaction
HEPATITIS is the #17 most commonly reported adverse reaction for PYRAZINAMIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 253 FDA adverse event reports linking PYRAZINAMIDE to HEPATITIS. This represents approximately 1.5% of all 17,268 adverse event reports for this drug.
Patients taking PYRAZINAMIDE who experience hepatitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATITIS is a less commonly reported adverse event for PYRAZINAMIDE, but still significant enough to appear in the safety profile.
In addition to hepatitis, the following adverse reactions have been reported for PYRAZINAMIDE:
The following drugs have also been linked to hepatitis in FDA adverse event reports:
HEPATITIS has been reported as an adverse event in 253 FDA reports for PYRAZINAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATITIS accounts for approximately 1.5% of all adverse event reports for PYRAZINAMIDE, making it a notable side effect.
If you experience hepatitis while taking PYRAZINAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.